Novavax (NVAX) Cash & Current Investments (2010 - 2026)

Novavax's Cash & Current Investments history runs 17 years deep, the most recent figure standing at $790.3 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 65.07% year-over-year to $790.3 million in Q1 2026; TTM through Mar 2026 was $790.3 million, a 65.07% increase from a year earlier, with the FY2025 full-year figure at $505.3 million, up 25.23% from the prior year.
• Cash & Current Investments climbed to $790.3 million in Q1 2026 per NVAX's latest filing, from $505.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $1.6 billion in Q1 2022 and bottomed at $10.3 million in Q2 2022.
• The 5-year median for Cash & Current Investments is $505.9 million (2023), against an average of $545.6 million.
• Across the five-year window, Cash & Current Investments slumped 99.5% in 2022 and surged 5937.13% in 2023, its largest moves.
• Year by year, Cash & Current Investments stood at $10.3 million in 2022, then surged by 5417.86% to $568.5 million in 2023, then decreased by 29.02% to $403.5 million in 2024, then climbed by 25.23% to $505.3 million in 2025, then soared by 56.4% to $790.3 million in 2026.
• Per Business Quant, the three latest NVAX Cash & Current Investments figures stand at $790.3 million (Q1 2026), $505.3 million (Q4 2025), and $762.9 million (Q3 2025).